BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -3.77 CHF | 42.0% |
| 2022 | -6.50 CHF | 11.08% |
| 2021 | -7.31 CHF | -158.57% |
| 2020 | 12.48 CHF | 2.04% |
| 2019 | 12.23 CHF | 243.71% |
| 2018 | -8.51 CHF | -168.52% |
| 2017 | 12.42 CHF | 185.6% |
| 2016 | -14.51 CHF | -224.12% |
| 2015 | 11.69 CHF | -54.97% |
| 2014 | 25.96 CHF | 58.78% |
| 2013 | 16.35 CHF | 160.35% |
| 2012 | 6.28 CHF | 790.11% |
| 2011 | -0.91 CHF | 50.81% |
| 2010 | -1.85 CHF | -520.45% |
| 2009 | 0.44 CHF | -13.73% |
| 2008 | 0.51 CHF | 120.48% |
| 2007 | -2.49 CHF | -198.81% |
| 2006 | 2.52 CHF | -4.55% |
| 2005 | 2.64 CHF | 62.96% |
| 2004 | 1.62 CHF | 17.39% |
| 2003 | 1.38 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -2.87 CHF | -79.38% |
| 2024 Q1 | 4.75 CHF | 138.69% |
| 2024 Q2 | -1.60 CHF | -133.68% |
| 2023 FY | - CHF | 42.0% |
| 2023 Q4 | 1.99 CHF | 323.6% |
| 2023 Q3 | -0.89 CHF | -270.83% |
| 2023 Q2 | -0.24 CHF | 94.82% |
| 2023 Q1 | -4.63 CHF | -623.44% |
| 2022 FY | - CHF | 11.08% |
| 2022 Q4 | -0.64 CHF | -116.71% |
| 2022 Q2 | -4.23 CHF | 22.1% |
| 2022 Q3 | 3.83 CHF | 190.54% |
| 2022 Q1 | -5.43 CHF | 44.98% |
| 2021 FY | - CHF | -158.57% |
| 2021 Q1 | 3.99 CHF | -66.39% |
| 2021 Q2 | 2.32 CHF | -41.85% |
| 2021 Q3 | -3.76 CHF | -262.07% |
| 2021 Q4 | -9.87 CHF | -162.5% |
| 2020 Q3 | -7.13 CHF | -133.49% |
| 2020 FY | - CHF | 2.04% |
| 2020 Q4 | 11.87 CHF | 266.48% |
| 2020 Q2 | 21.29 CHF | 255.63% |
| 2020 Q1 | -13.68 CHF | -250.16% |
| 2019 Q4 | 9.11 CHF | 232.22% |
| 2019 Q2 | -6.07 CHF | -137.77% |
| 2019 Q1 | 16.07 CHF | 239.01% |
| 2019 FY | - CHF | 243.71% |
| 2019 Q3 | -6.89 CHF | -13.51% |
| 2018 Q4 | -11.56 CHF | -364.53% |
| 2018 Q2 | -1.78 CHF | -449.02% |
| 2018 FY | - CHF | -168.52% |
| 2018 Q1 | 0.51 CHF | 118.15% |
| 2018 Q3 | 4.37 CHF | 345.51% |
| 2017 Q4 | -2.81 CHF | -142.64% |
| 2017 Q3 | 6.59 CHF | 252.41% |
| 2017 Q2 | 1.87 CHF | -72.42% |
| 2017 FY | - CHF | 185.6% |
| 2017 Q1 | 6.78 CHF | 1640.91% |
| 2016 Q4 | -0.44 CHF | -106.14% |
| 2016 Q1 | -21.84 CHF | -336.11% |
| 2016 Q3 | 7.17 CHF | 1020.31% |
| 2016 FY | - CHF | -224.12% |
| 2016 Q2 | 0.64 CHF | 102.93% |
| 2015 Q3 | -10.32 CHF | -271.71% |
| 2015 FY | - CHF | -54.97% |
| 2015 Q4 | 9.25 CHF | 189.63% |
| 2015 Q2 | 6.01 CHF | -10.96% |
| 2015 Q1 | 6.75 CHF | -48.63% |
| 2014 Q4 | 13.14 CHF | 54.04% |
| 2014 Q3 | 8.53 CHF | 147.25% |
| 2014 Q2 | 3.45 CHF | 200.0% |
| 2014 FY | - CHF | 58.78% |
| 2014 Q1 | 1.15 CHF | -36.81% |
| 2013 Q2 | 2.28 CHF | -63.98% |
| 2013 Q3 | 5.98 CHF | 162.28% |
| 2013 Q4 | 1.82 CHF | -69.57% |
| 2013 FY | - CHF | 160.35% |
| 2013 Q1 | 6.33 CHF | 360.49% |
| 2012 Q2 | 2.17 CHF | -30.0% |
| 2012 Q3 | 2.01 CHF | -7.37% |
| 2012 Q4 | -2.43 CHF | -220.9% |
| 2012 Q1 | 3.10 CHF | 58.16% |
| 2012 FY | - CHF | 790.11% |
| 2011 Q3 | -1.42 CHF | -54.35% |
| 2011 Q1 | 0.53 CHF | -56.2% |
| 2011 FY | - CHF | 50.81% |
| 2011 Q4 | 1.96 CHF | 238.03% |
| 2011 Q2 | -0.92 CHF | -273.58% |
| 2010 Q3 | 0.37 CHF | 110.36% |
| 2010 Q4 | 1.21 CHF | 227.03% |
| 2010 Q1 | 0.51 CHF | 138.35% |
| 2010 FY | - CHF | -520.45% |
| 2010 Q2 | -3.57 CHF | -800.0% |
| 2009 Q2 | 1.12 CHF | 200.0% |
| 2009 Q3 | 1.07 CHF | -4.46% |
| 2009 Q4 | -1.33 CHF | -224.3% |
| 2009 FY | - CHF | -13.73% |
| 2009 Q1 | -1.12 CHF | 0.0% |
| 2008 FY | - CHF | 120.48% |
| 2007 FY | - CHF | -198.81% |
| 2006 FY | - CHF | -4.55% |
| 2005 FY | - CHF | 62.96% |
| 2004 FY | - CHF | 17.39% |
| 2003 FY | - CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Addex Therapeutics Ltd | -0.14 CHF | -2592.857% |
| Basilea Pharmaceutica AG | 0.87 CHF | 533.333% |
| Evolva Holding SA | -19.50 CHF | 80.667% |
| Idorsia Ltd | -1.67 CHF | -125.749% |
| Kuros Biosciences AG | -0.38 CHF | -892.105% |
| Molecular Partners AG | -1.89 CHF | -99.471% |
| Relief Therapeutics Holding AG | -8.35 CHF | 54.85% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 172.78% |